RESEARCH PROGRESS

Kerun biology has transferred three products in China and listed one product, five indications have been approved, and two products have carried out two clinical trials nationwide. Among them, the company's first heavyweight product, the first domestic exclusive and clinically urgently needed new biological drug independently developed by the company, is currently carrying out phase II / III clinical trials, carrying out clinical trials according to the number of cases combined and reduced in phase II / III, applying for conditional approval for listing, planning to complete clinical research in 2023 and apply for listing in 2024.

The second product K07 project is urgently needed drugs to replace imported varieties, directly repair damaged corneal nerve cells and completely cure the disease. It is expected to complete the phase I clinical experiment in 2022 and apply for listing at the end of 2024.

OPHTHALMIC DRUGS

OTHER PROTEIN DRUGS

PRODUCT PIPELINE